 | |
Displaying ofatumumab PowerPoint Presentations
Presentation Summary : 0.50 0.27 0.27 0.11 0.13 0.02 Ofatumumab. Placebo. 0.50 0.27 0.27 0.11 0.13 0.02 Sheet1. Chart1. To update the chart, enter data into this table.
Source : http://www.medpagetoday.com/upload/2011/7/6/mpt_sld.ppt
Understanding the - U S Food and Drug Administration Home Page PPT
Presentation Summary : ... Ofatumumab approved for the treatment of CLL refractory to alemtuzumab and fludarabine Valuable Resources Orphan Designation Highlights: ...
Source : http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/OOPDNewsArchive/UCM324031.ppt
Clinical Trials in Rare Diseases - Health Research Board: About PPT
Presentation Summary : CHMP ASSESSMENT REPORT for Arzerra (ofatumumab) Procedure No. EMEA/H/C/001131 London: EMA 2010 . Title: Clinical Trials in Rare Diseases Author: Catherine Gill
Source : http://www.hrb.ie/uploads/media/Prof_Brendan_Buckley.ppt
Presentation Summary : Ofatumumab rapidly metabolized by hydrolyis of ester linkage; carboxylic acid metabolims further metabolized by glucorondination or oxidation Clevidipine Butyrate
Source : http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM272709.ppt
Presentation Summary : Panobinostat Open studies Ofatumumab anti-CD20 monoclonal Ab Panobinostat epigenetic ...
Source : http://www.wmuk.org.uk/documents/Rebecca%20Auer-%20WM-The%20Future.ppt
Diapositive 1 - Campus Virtuel de Lille2 PPT
Presentation Summary : Human mAb Ofatumumab recognizes a membrane proximal conformational epitope consisting of the small extracellular loop. Arzerra’s innovations. Rituximab.
Source : http://campus2.univ-lille2.fr/claroline/backends/download.php?url=LzIwMTBfLV9Qcm9kdWN0aW9uX2RlX3Byb3RlaW5lc19jaGV6X2xlX2FuaW1hdXhfdHJhbnNn6G5pcXVlcy5wcHR4&cidReset=true&cidReq=SEMCOM
Chronic Lymphocytic Leukemia PPT
Presentation Summary : ... Riuximab, Ofatumumab Active immunotherapy Tumor associated antigens (TAA) and vaccines Stem cell transplantation Cancer Control: January 2012, Vol.19, ...
Source : http://www.nholua.com/documents/Chronic%20Lymphocytic%20Leukemia.ppt
Presentation Summary : ... 1 mg G 9259 C9260 J9302 Injection, ofatumumab, 10 mg G 9260 C9261 J3357 Injection, ustekinumab, 1 mg G 9261 C9263 J1290 Injection, ecallantide, ...
Source : http://hfmawny.org/LinkClick.aspx?fileticket=nrenWfq1w-0%3d&tabid=39
Presentation Summary : ... ORR of ofatumumab + chemo Results and Relevance to Practice Results CR 22 pts (37%) ORR 36pts (61%) Median PFS 9-6 months Median OS 16 ...
Source : http://www.mccn.nhs.uk/fileuploads/File/ASH%20Highlights%202011_vs5.ppt
Results of a multicenter randomized study comparing the ... PPT
Presentation Summary : ... FCR ? CLB+R or CLB+O or CLB+GA101 MAb monotherapy (R, Ofatumumab, GA 101..) First-line treatments in WM 20% of the patients have a first ...
Source : http://www.hematotunisie.org/fr/abstract_book/WALTUNISIe.ppt
B-Cells and the Use of Rituximab in MS PPT
Presentation Summary : ... % human & 35-40% mouse protein Increased allergic reactions In development: Ocrelizumab - 90-95% humanized anti-CD 20 Ofatumumab (or 2H7) ...
Source : http://faculty.ksu.edu.sa/daif/lectures/Rituximab%20and%20multiple%20sclerosis.ppt
Overall survival in relapsed/refractory FL patients PPT
Presentation Summary : ... PRIMA like criteria Number planned = 82 patients Other anti CD20 in FL Antibody Manufacturer Type Source Trials Ofatumumab Genmab Type I Human 2 Phase III ...
Source : http://www.hematotunisie.org/fr/31-05/Morschhauser_FL_Sousse25-1-.ppt
Medicare 2010-2011 - POHMS | Welcome to the Premier Oncology ... PPT
Presentation Summary : Reimbursement 2012 Bobbi Buell MBA 800-795-2633 * * onPoint Oncology LLC * Contact bbuell@covad.net bobbibuell1@yahoo.com 800-795-2633 Newsletter is free!
Source : http://pohms.com/aws/POHMS/asset_manager/get_file/44810
